Johnson & Johnson’s Tremfya outperforms IL-17 inhibitors for the treatment of plaque psoriasis

On March 17, 2023, Janssen Pharmaceuticals of Johnson & Johnson (J&J), a leading biopharmaceutical company, announced the launch of Tremefia (guselkumab), a monoclonal antibody that binds to the p19 subunit of interleukin-23. The latest results obtained from real-world data analysis were presented. (IL-23) is associated with IL-23 receptors in bionaïve and bioexperienced moderate-to-severe plaque psoriasis (PsO) patients eligible for systemic therapy or phototherapy. interfere with interactions. According to reported data, Tremfya showed superior long-term control of her PsO symptoms compared to the IL-17 inhibitors secukinumab and ixekizumab, resulting in a significant improvement in quality of life (Johnson & Johnson, 2023 ).

PsO is a systemic immune-mediated skin disease that affects 2%–3% of the world’s population and is associated with physical consequences and poor quality of life (Damiani et al., 2021). J&J’s Tremfya is the first and only fully human selective IL-23 inhibitor therapy approved in the US for her patients with moderate to severe PsO. Administered intravenously or subcutaneously, Tremfya 100 mg selectively targets the p19 subunit of IL-23 and binds with high affinity to IL-23, a key driver and inflammatory cytokine in the pathogenesis of psoriasis. inhibits its interaction with and signaling. .

Real-world data analysis conducted using IBM MarketScan Research Databases showed Tremfya to be superior to secukinumab and ixekizumab in treatment retention and moderate to severe disease in bioexperienced and bioexperienced was associated with long-term control of PsO symptoms. . In the bionaive patient group, the Tremfya cohort showed 2.20-fold longer persistence at 12 months and 2.28-fold longer at 18 months compared with secukinumab his cohort. When compared with the isekizumab cohort, the Tremfya group showed 1.84 longer treatment duration at 12 months and 1.86 longer treatment duration at 18 months. Among bioexperienced adults, the Tremfya cohort showed 2.00 and 2.04 times longer treatment retention at 12 and 18 months, respectively, compared to the secukinumab cohort. In addition, patients receiving Tremfya had 1.76-fold and 1.67-fold longer duration compared to cohorts receiving ixekizumab at 12 and 18 months, respectively.

Tremfya’s established efficacy was reinforced by results from J&J’s randomized, double-blind, placebo-controlled and active comparator-controlled Phase III VOYAGE 2 (NCT02207244) clinical trial. The study demonstrated superior and durable clinical efficacy of Tremfya, including changes in Mean Psoriasis Symptom Diary (PSSD) Itching Score and improved quality of life in adult patients with scalp PsO compared to placebo and AbbVie’s Humira (adalimumab). demonstrated efficacy and safety. , is a blockbuster and a direct competitor in this field. Tremfya responders (defined as patients achieving at least 90% improvement in the Psoriasis Area and Severity Index 90 score) had a scalp-specific Investigator Global Assessment (ss-IGA) mean score ranging from 2.9 to 2.9 at Week 0 It improved rapidly to 0.2 and 0.3. 24, 48 respectively. J&J reported that changes in the mean PSSD itch score and dermatological life quality index score were consistent with those noted in the mean ss-IGA score for all Tremfya cohorts tested.

Data presented by Janssen at the 2023 American Academy of Dermatology Annual Meeting highlight the ability and potential of Tremfya to provide superior long-term control of PsO symptoms when compared to secukinumab and ikekizumab. The positive results, its unique mechanism of action targeting the p19 subunit of IL-23, and its proven efficacy in scalp PsO make it a valuable management and treatment option for patients with moderate to severe PsO. emphasizes Tremfya’s role as

With global sales projected to reach $8.6 billion by 2029 by analyst consensus, according to GlobalData’s pharmaceutical database Pharma Intelligence Center, Tremfya has become a blockbuster PsO treatment, including rivalry. It will directly compete with the formidable established biologics in this field. AbbVie’s Humira. Overall, GlobalData understands that the positive results position Tremfya as a leading agent in his growing PsO space. Janssen’s commitment to developing effective treatments for his PsO, especially in a difficult-to-treat area, has resulted in continued research and development of drugs like Tremfya and improved quality of life for those affected by PsO. It’s clear from the focus.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *